At Kedrion Biopharma, we have always focused on the research and development of plasma-derived orphan drugs intended for the treatment of rare diseases. Unmet medical needs led us to establish a plant in Siena, Italy, in 2011. Renamed IKOD (Kedrion Orphan Drugs Plant), these facilities are part of a collaboration between Kedrion Biopharma and Toscana Life Sciences Foundation and, in October 2015, they were granted the authorization to produce biological hemoderived experimental therapies for clinical testing by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA).
In the following video, Lorenzo Terranova, IKOD QA Manager and Qualified Person, tells the story of Kedrion Biopharma’s dedication to developing the right treatment for particularly rare diseases.
